搜尋結果

共 1994 個結果
頁數:1...12 13 14 15 16 17 18 19 20 ...100

越秀房產信託基金(00405) 有關集體投資計劃事宜

越秀房產信託基金(00405) 公佈 - 為受COVID-19影響的租戶提供臨時租金減免(268KB, pdf ...全文

即時新聞港交所通告2022年06月10日

Building smarter healthcare in HK with intelligent automation

That Hong Kong's healthcare system had been under enormous strain is no secret. By the end of March, the territory's COVID-19 numbers had peaked at more than 55,000 infections. Set against the city's ...More

EJ Insight2022-06-09

What biotech innovation needs

The COVID-19 pandemic has reshaped attitudes toward public health, fiscal policy, and the state’s role in the economy. Demands for greater supply-chain resilience and strategic autonomy in developing ...More

EJ Insight2022-06-07

The global economy in transition

... ffects of COVID-19 lockdowns, low vaccination uptake among the elderly, some loss of investor confidence in high-growth tech sectors, and a real-estate sector beset by high debts and falling prices. T ...More

EJ Insight2022-06-07

全球糧食危機的黑天鵝

... 。在戰爭、全球暖化及COVID-19的共同影響下,聯合國世界糧食計劃署(WFP)便估計,全球受飢餓所困擾的人會 ...全文

今日信報時事評論龍子維2022年06月07日

烏克蘭戰事加劇全球不安失序

... 有77%的人口未接種COVID-19疫苗,成為變種病毒溫床。 相比2010年,除了生活成本上漲之外,今天可以促 ...全文

今日信報時事評論黃伯農2022年06月07日

China’s Covid struggle: It’s about ideology, not health

Last month, when the Covid-19 death toll in the United States reached a million, China’s government and state media took delight in mocking and shaming America in its moment of national grief. A Chine ...More

EJ Insight2022-06-06

學術上的命名

... 新冠病毒的官方名稱是COVID-19,其中英文字是Corona Virus Disease(冠狀病毒疾病)的簡 ...全文

今日信報副刊文化康和健顧小培2022年06月06日

Getting deglobalization right

... s without COVID-19 vaccines just so that a few drug companies could earn billions in extra profits. Among the proposed responses to these problems are to “reshore” or “friend-shore” production and to ...More

EJ Insight2022-06-03

北韓稱疫情緩和 世衞憂情況更嚴峻

... 。 平壤不曾直接證實COVID-19檢測陽性病例數。專家懷疑,政府把持的國營媒體低報數字,難以評估疫情規模。與 ...全文

即時新聞時事脈搏2022年06月02日

韓防彈少年團晤拜登 宣揚反仇亞
亮相白宮記招 傳媒逼爆31萬人看直播

... 恨犯罪法》(The COVID-19 Hate Crimes Act),以及讚揚對方致力尋找解決方法,並希望在 ...全文

今日信報EJ Global2022年06月02日

Don’t bet on a soft landing

... sponse to COVID-19 had led to lockdowns, which caused major disruptions to global supply chains and reduced the supply of workers (creating a very tight labor market in the US). Then came two addition ...More

EJ Insight2022-06-01

How will China’s currency respond to slower growth?

... tbreak of COVID-19 that has led to lockdowns. The Rise of the Chinese Dragon China’s economy began its metamorphosis into what it is today with reforms initiated by Deng Xiaoping in the 1970s and 1980 ...More

EJ Insight2022-06-01

脫歐後優勢盡失

... 民保健署NHS發出的COVID-19通行證,或者填好Spanish Travel Ministry(SpTH) ...全文

今日信報副刊文化盡付笑談毛羨寧2022年05月31日

Reducing plastic pollution at source

The fifth wave of COVID-19 epidemic in Hong Kong has been severe. In order to curb the spread of the epidemic, the government adopted stricter anti-epidemic measures, including banning dining in resta ...More

EJ Insight2022-05-30

Has the US damaged Africa’s COVID-19 vaccination drive?

The United States Food and Drug Administration’s recent decision to limit the use of the Johnson & Johnson COVID-19 vaccine to adults who cannot or will not get another vaccine will have profound ...More

EJ Insight2022-05-27

The global hunger crisis is here

... nger. The COVID-19 pandemic exposed the fragility and dysfunctionality of the world’s food systems, with movement restrictions and supply-chain disruptions driving up prices, damaging rural livelihood ...More

EJ Insight2022-05-24

開市焦點:納期今早挫1.3% 港股考驗20天線 留意車股

... 物(01877)稱,Covid-19口服藥物VV116片達到方案預設的主要終點,公 司將於近期與監管部門溝通遞 ...全文

即時新聞港股直擊2022年05月24日

君實生物(01877) (修改後標題) 公告及通告 - [內幕消息]

君實生物(01877) 內幕消息- VV116對比PAXLOVID早期治療輕中度COVID-19的III期註冊 ...全文

即時新聞港交所通告2022年05月24日

君實生物(01877) 海外監管公告-業務發展最新情況

... VID早期治療輕中度COVID-19的III期註冊臨床研究達到主要研究終點的公告(311KB, pdf) ...全文

即時新聞港交所通告2022年05月23日

頁數:1...12 13 14 15 16 17 18 19 20 ...100

信報簡介 | 服務條款 | 私隱條款 | 免責聲明 | 廣告查詢 | 加入信報 | 聯絡信報

股票及指數資料由財經智珠網有限公司提供。期貨指數資料由天滙財經有限公司提供。外滙及黃金報價由路透社提供。

本網站的內容概不構成任何投資意見,本網站內容亦並非就任何個別投資者的特定投資目標、財務狀況及個別需要而編製。投資者不應只按本網站內容進行投資。在作出任何投資決定前,投資者應考慮產品的特點、其本身的投資目標、可承受的風險程度及其他因素,並適當地尋求獨立的財務及專業意見。本網站及其資訊供應商竭力提供準確而可靠的資料,但並不保證資料絕對無誤,資料如有錯漏而令閣下蒙受損失,本公司概不負責。